Table 1 Patient characteristics by BMI categories.

Age (years)

0.002

 <49

239

162

77

–

 ≥49

252

137

115

–

Menopausal status

0.098

 Premenopausal

291

188

103

–

 Postmenopausal

195

109

86

–

 Unknown

5

2

3

–

Clinical T stage

0.104

 T1-2

372

219

153

–

 T3-4

119

80

39

–

Nodal status

0.452

 Negative

111

71

40

–

 Positive

380

228

152

–

Hormone receptor

0.132

 Negative

240

138

102

–

 Positive

251

161

90

–

HER2 staining intensity

0.425

 2+

40

22

18

–

 3+

451

277

174

–

Ki67 (%)

0.943

 <40

203

124

79

–

 ≥40

288

175

113

–

Neoadjuvant targeted therapy

0.676

 Trastuzumab

358

216

142

–

 Trastuzumab plus Pertuzumab

133

83

50

–

Pathological response

0.008

 Non-pCR

302

170

132

–

 pCR

189

129

60

–